

Table 6. Patient characteristics at baseline in the randomized groups by diabetes status.

Characteristic	Diabetes			No diabetes		
	Ticagrelor (N=2326)	Clopidogrel (N=2336)	p	Ticagrelor (N=6999)	Clopidogrel (N=6952)	p
Age, median (25th - 75th percentile)	64 (56 - 72)	64 (56 - 72)	0.738	61 (53 - 70)	61 (53 - 70)	0.745
Age ≥ 75 yrs % (n)	17.1 (398)	17.6 (411)	0.663	14.2 (997)	15.4 (1070)	0.163
Gender, women, % (n)	33.9 (789)	35.7 (835)	0.191	26.6 (1865)	25.8 (1795)	0.267
Body weight median (25th - 75th percentile)	82 (71 - 94)	80 (70 - 92)	0.061	79 (70 - 89)	79 (70 - 89)	0.873
Body weight < 60 kg, % (n)	5.5 (128)	6.3 (146)	0.114	7.5 (524)	7.4 (514)	0.966
BMI median (25th - 75th percentile)	28.8 (25.7 - 32.4)	28.4 (25.7 - 31.9)	0.134	27.0 (24.5 - 29.9)	27.0 (24.4 - 29.8)	0.260
Waist circumference, median (25th - 75th percentile)	102 (93 - 110)	102 (92 - 111)	0.736	96 (89 - 105)	97 (89 - 105)	0.575
Race, % (n)			0.747			0.930
Black	2.3 (53)	1.9 (45)		0.9 (62)	1.0 (69)	
Caucasian	89.6 (2083)	89.3 (2086)		92.5 (6476)	92.4 (6422)	
Oriental	6.6 (154)	7.1 (165)		5.5 (388)	5.6 (389)	
Other	1.5 (36)	1.7 (40)		1.0 (73)	1.0 (72)	
CV Risk Factors, % (n)						
Habitual smoker	24.6 (573)	25.0 (583)	0.799	39.8 (2787)	39.4 (2735)	0.577

Hypertension	81.8 (1902)	81.3 (1900)	0.701	60.5 (4237)	59.6 (4144)	0.263
Dyslipidemia	58.5 (1361)	60.8 (1421)	0.107	42.7 (2986)	42.0 (2921)	0.435
History, % (n)						
Angina pectoris	53.2 (1238)	54.8 (1279)	0.296	42.6 (2982)	41.1 (2859)	0.076
Myocardial infarction	27.0 (629)	27.1 (632)	0.992	18.2 (1271)	18.6 (1292)	0.517
Congestive heart failure	9.0 (209)	9.9 (231)	0.291	4.3 (304)	4.4 (306)	0.867
Percutaneous coronary intervention	18.4 (428)	17.9 (419)	0.681	12.1 (844)	11.5 (801)	0.327
Coronary artery bypass graft	10.4 (242)	9.5 (222)	0.304	4.1 (290)	5.1 (352)	0.010
Transient ischemic attack	3.1 (72)	3.6 (85)	0.304	2.5 (174)	2.4 (168)	0.791
Non-hemorrhagic stroke	5.4 (126)	6.1 (143)	0.302	3.2 (227)	3.3 (226)	0.979
Peripheral arterial disease	8.8 (204)	9.7 (227)	0.264	5.2 (362)	5.0 (351)	0.741
Chronic renal disease	7.6 (176)	8.0 (186)	0.614	2.9 (203)	3.2 (220)	0.363
OL ³ Clopidogrel before randomization \geq 600, % (n)	9.4 (219)	8.6 (202)	0.360	13.4 (937)	13.1 (909)	0.586
Total clopidogrel (OL+IP) ¹ dose \geq 600 mg before randomisation to 24 h after first dose	16.7 (388)	16.1 (377)	0.617	22.3 (1562)	21.8 (1518)	0.492
Planned invasive, % (n)	65.8 (1530)	67.6 (1579)	0.188	74.2 (5195)	73.3 (5094)	0.202
Baseline labs, median (25th - 75th percentile)						
Glucose, mmol/L	9.6 (7.1 - 13.0)	9.9 (7.3 - 13.4)	0.038	6.4 (5.6 - 7.8)	6.4 (5.6 - 7.7)	0.050

HbA1c, %	7.6 (6.7 - 8.9)	7.6 (6.6 - 9.1)	0.698	5.8 (5.6 - 6.1)	5.8 (5.6 - 6.1)	0.575
Creatinine clearance, ml/min	76.5 (58.4 - 97.0)	76.2 (57.6 - 96.4)	0.568	81.7 (65.4 - 100)	81.5 (64.1 - 99.1)	0.137
First central troponin I ² , umol/L	2.1 (0.2 - 12.1)	2.1 (0.2 - 11.0)	0.881	2.0 (0.2 - 11.8)	2.3 (0.2 - 12.5)	0.030

¹ OL = Open label and IP= Investigational product

² Advia Centaur TnI-Ultra Immunoassay (Siemens).

Table 7: Patient procedures in the randomized groups by diabetes status.

Characteristic	Diabetes			No diabetes		
	Ticagrelor (N=2326)	Clopidogrel (N=2336)	P	Ticagrelor (N=6999)	Clopidogrel (N=6952)	P
Medications from index event to end of hospitalization, % (n)						
Aspirin	97.2 (2262)	96.9 (2263)	0.501	97.2 (6797)	97.3 (6752)	0.662
Beta-blockers	83.8 (1950)	83.5 (1949)	0.736	86.2 (6029)	86.6 (6013)	0.436
ACE-inhibitors and/or Angiotensin Receptor blockers	89.7 (2086)	89.9 (2100)	0.774	81.1 (5674)	80.9 (5613)	0.722
Cholesterol lowering (Statin)	93.6 (2176)	93.5 (2183)	0.933	94.0 (6576)	94.0 (6523)	0.963
Ca-channel blockers	30.0 (697)	29.5 (688)	0.708	18.4 (1289)	19.4 (1349)	0.128
Diuretics	49.7 (1156)	49.0 (1145)	0.651	34.4 (2403)	33.0 (2289)	0.087
Glycoprotein IIb/IIIa inhibitors	22.9 (533)	25.1 (586)	0.083	28.3 (1980)	27.9 (1938)	0.587
Insulin	54.8 (1275)	55.6 (1298)	0.595	5.8 (407)	5.2 (359)	0.094
Any anti-diabetic medication	84.4 (1964)	83.9 (1960)	0.642	6.6 (464)	6.1 (422)	0.181
Procedures, % (n)						
Coronary angiography before discharge	76.7 (1784)	78.0 (1823)	0.274	83.1 (5814)	82.7 (5748)	0.543
Coronary angiography during study	82.3 (1914)	83.4 (1949)	0.299	87.1 (6093)	86.6 (6023)	0.465
PCI before discharge	52.8 (1227)	55.1 (1287)	0.109	63.7 (4460)	63.1 (4389)	0.469
PCI during study	56.6 (1316)	59.4 (1387)	0.053	66.6 (4662)	66.3 (4612)	0.737

Stenting	52.8 (1229)	55.3 (1291)	0.096	63.0 (4411)	62.7 (4358)	0.681
With bare-metal stent only	32.5 (756)	33.5 (782)	0.480	45.2 (3165)	44.7 (3110)	0.564
With ≥ 1 drug-eluting stent	20.3 (473)	21.8 (509)	0.223	17.8 (1246)	18.0 (1248)	0.818
CABG before discharge	5.9 (138)	6.9 (162)	0.163	4.7 (327)	4.9 (343)	0.470
CABG during study	13.1 (304)	13.4 (313)	0.740	9.0 (627)	9.4 (655)	0.344
Final diagnosis ¹ , % (n)			0.848			0.494
NSTEMI	48.4 (1125)	46.7 (1092)		41.1 (2880)	41.1 (2858)	
Other	2.7 (62)	2.9 (68)		2.8 (197)	2.3 (162)	
STEMI	28.2 (655)	29.2 (681)		40.6 (2841)	41.0 (2849)	
Unstable angina pectoris	20.7 (482)	21.1 (493)		15.2 (1067)	15.4 (1070)	

¹ Type of ACS defined using final diagnosis of index event.

Table 8. Glucose / HbA1c by treatment interactions in patients without diabetes

	N	Overall	Ticagrelor	Clopidogrel	HR (95% CI)	P (interaction)
Cardiovascular death, myocardial infarction, or stroke						
Glucose < 6.4 mmol/L ¹	5503	8.4 (430)	7.4 (186)	9.5 (244)	0.78 (0.64 - 0.94)	0.71
Glucose ≥ 6.4 mmol/L ¹	5904	10.2 (572)	9.4 (270)	11.0 (302)	0.86 (0.73 - 1.02)	
HbA1c < 5.8% ¹	4798	8.4 (383)	8.3 (193)	8.6 (190)	1.01 (0.83 - 1.24)	0.04
HbA1c ≥ 5.8% ¹	6545	9.9 (611)	8.5 (259)	11.4 (352)	0.73 (0.62 - 0.85)	
All cause death						
Glucose < 6.4 mmol/L ¹	5503	3.3 (162)	2.6 (65)	3.9 (97)	0.69 (0.50 - 0.94)	0.48
Glucose ≥ 6.4 mmol/L ¹	5904	5.3 (293)	4.7 (135)	5.9 (158)	0.83 (0.66 - 1.04)	
HbA1c < 5.8% ¹	4798	3.7 (166)	3.1 (70)	4.4 (96)	0.72 (0.53 - 0.98)	0.63
HbA1c ≥ 5.8% ¹	6545	4.6 (283)	4.1 (126)	5.2 (157)	0.80 (0.63 - 1.01)	
Myocardial infarction						
Glucose < 6.4 mmol/L ¹	5503	5.8 (297)	5.1 (129)	6.5 (168)	0.78 (0.62 - 0.99)	0.80
Glucose ≥ 6.4 mmol/L ¹	5904	5.7 (312)	5.1 (144)	6.2 (168)	0.83 (0.66 - 1.03)	

HbA1c < 5.8% ¹	4798	5.4 (243)	5.3 (124)	5.5 (119)	1.03 (0.80 - 1.33)	0.03
HbA1c ≥ 5.8% ¹	6545	6.0 (364)	5.0 (149)	7.0 (215)	0.68 (0.56 - 0.84)	
Definite stent thrombosis						
Glucose < 6.4 mmol/L ¹	3136	1.0 (30)	1.2 (17)	0.8 (13)	1.29 (0.63 - 2.65)	0.23
Glucose ≥ 6.4 mmol/L ¹	4049	1.7 (69)	1.3 (26)	2.2 (43)	0.60 (0.37 - 0.98)	
HbA1c < 5.8% ¹	3052	1.4 (41)	1.3 (18)	1.5 (23)	0.76 (0.41 - 1.41)	0.08
HbA1c ≥ 5.8% ¹	4108	1.5 (58)	1.3 (25)	1.6 (33)	0.75 (0.45 - 1.27)	
Major bleeding, PLATO defined						
Glucose < 6.4 mmol/L ¹	5503	10.5 (516)	10.7 (257)	10.2 (259)	1.02 (0.86 - 1.21)	0.04
Glucose ≥ 6.4 mmol/L ¹	5904	9.8 (526)	10.8 (295)	8.8 (231)	1.25 (1.05 - 1.49)	
HbA1c < 5.8% ¹	4798	9.1 (400)	10.3 (224)	8.0 (176)	1.28 (1.05 - 1.56)	0.74
HbA1c ≥ 5.8% ¹	6545	10.9 (643)	11.3 (332)	10.6 (311)	1.07 (0.92 - 1.25)	
Non-CABG related major bleeding, PLATO defined						
Glucose < 6.4 mmol/L ¹	5503	3.5 (164)	3.8 (88)	3.1 (76)	1.19 (0.88 - 1.62)	0.24
Glucose ≥ 6.4 mmol/L ¹	5904	3.9 (205)	4.4 (118)	3.3 (87)	1.32 (1.00 - 1.75)	

HbA1c < 5.8% ¹	4798	3.4 (147)	4.3 (91)	2.5 (56)	1.63 (1.17 - 2.28)	0.64
HbA1c ≥ 5.8% ¹	6545	3.8 (218)	4.1 (116)	3.6 (102)	1.14 (0.88 - 1.49)	
CABG related major bleeding, PLATO defined						
Glucose < 6.4 mmol/L ¹	5503	7.3 (367)	7.1 (174)	7.6 (193)	0.93 (0.76 - 1.14)	0.23
Glucose ≥ 6.4 mmol/L ¹	5904	6.3 (334)	6.7 (181)	5.9 (153)	1.15 (0.93 - 1.43)	
HbA1c < 5.8% ¹	4798	6.0 (263)	6.1 (133)	6.0 (130)	1.02 (0.80 - 1.30)	0.73
HbA1c ≥ 5.8% ¹	6545	7.5 (443)	7.6 (225)	7.4 (218)	1.04 (0.86 - 1.25)	
Major bleeding, TIMI defined						
Glucose < 6.4 mmol/L ¹	5503	7.3 (359)	7.4 (181)	7.1 (178)	1.05 (0.85 - 1.29)	0.30
Glucose ≥ 6.4 mmol/L ¹	5904	6.9 (370)	7.6 (207)	6.1 (163)	1.24 (1.01 - 1.52)	
HbA1c < 5.8% ¹	4798	6.5 (282)	7.0 (152)	5.9 (130)	1.17 (0.92 - 1.48)	0.51
HbA1c ≥ 5.8% ¹	6545	7.7 (454)	8.2 (242)	7.2 (212)	1.15 (0.96 - 1.38)	

¹The median of glucose and HbA1c is calculated from the cohort without diabetes